R. Faraawi

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
R Faraawi, R. Faraawi, Rafat Faraawi, Rafat Y Faraawi
Publication record
29 papers · 229 citations · H-index 7

PAPERS

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
202011 citationsauthor #8
FRI0109 EFFECTIVENESS AND SAFETY OF INFLIXIMAB, GOLIMUMAB AND GOLIMUMAB-IV IN RHEUMATOID ARTHRITIS PATIENTS FROM A PROSPECTIVE OBSERVATIONAL REGISTRY
20190 citationsauthor #4
Incidence of infusion reactions to intravenous golimumab: results from a prospective, real-world community registry.
20190 citationsauthor #1
AB0436 Consolidated long-term safety of infliximab in inflammatory arthritis from a prospective, observational registry
20183 citationsauthor #4
FRI0172 Primary and Secondary Non-Response in RA Patients Treated with An anti-TNF: An Analysis from A Prospective, Observational Registry
20160 citationsauthor #7
FRI0204 What is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction
20150 citationsauthor #6
Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry
201560 citationsauthor #2
SAT0557 Predictors of Response in Patients with Psoriatic Arthritis Treated with Anti-TNF in a Real-World Setting
20150 citationsauthor #7
SAT0168 What is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? An Analysis from a Real-World Registry
20150 citationsauthor #1
Prospective Real-world Community Registry Incidence and Management of Infusion Reactions to Infliximab in a
20150 citationsauthor #2
AB1163 Prevalence of Smoking and Impact on Disease Parameters Among Ankylosing Spondylitis, Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Infliximab or Golimumab
20151 citationsauthor #1
Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population
201524 citationsauthor #4
AB1059 Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in A Canadian Setting
20140 citationsauthor #10
SAT0035 Impact of Corticosteroid Use on Remission Sustainability and Infection Rates among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on A Real-World Population
20140 citationsauthor #4
AB0382 Factors Associated with the Incidence of Infusion Reactions to Infliximab: Results from “Remitrac Infusion”, A Prospective Real-World Community Registry
20140 citationsauthor #3
SAT0247 Safety of RAPID Rituximab Infusion in Rheumatoid Arthritis in A Single Community Practice
20144 citationsauthor #1
AB0302 Profile of Joint Involvement over Time in Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Anti-TNF in A Real-World Setting
20140 citationsauthor #7
FRI0047 Prediction of Remission by Patients and Physicians: Does the Doctor Know Best?
20141 citationsauthor #7
AB1044 Are There Gender Specific Differences in Patient Reported Outcomes at Initiation of Golimumab Treatment in Rheumatoid Arthritis?
20140 citationsauthor #8
AB0228 Variability in Patient Characteristics and Outcomes in Rheumatoid Arthritis upon Infliximab Treatment Based on the Size of the Biologic Treatment Registry Site
20140 citationsauthor #4
THU0241 Predictors of Acr/Eular Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: an Analysis from the Prospective, Observational Registry, Biotrac
20140 citationsauthor #11
THU0179 Corticosteroid Use in Rheumatoid Arthritis Patients on Infliximab: Treatment Implications Based on a Real-World Canadian Population
20130 citationsauthor #4
AB0421 Outcomes of infliximab treatment in canadian rheumatoid arthritis patients of different age groups
20130 citationsauthor #1
Rituximab Rapid Infusion : From Research to Practice
20110 citationsauthor #1
Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
200915 citationsauthor #2
W1238 The Remitrac Infusion Registry: Safety and Management of Infliximab Infusions in a Real-Life Setting
20081 citationsauthor #1
Septic arthritis due to Mycobacterium marinum.
199431 citationsauthor #3
Arthritis in hemochromatosis.
199368 citationsauthor #1
Escherichia coli emphysematous endophthalmitis and pyelonephritis. Case report and review of the literature.
198811 citationsauthor #1

TIMELINE

1988 11 citations

1993 68 citations

1994 31 citations

2008 1 citations

2009 15 citations

2011 0 citations

2013 0 citations

2014 5 citations

2015 85 citations

2016 0 citations

2018 3 citations

2019 0 citations

2020 11 citations

R. Faraawi

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT